Study of blood flow to the placenta during early pregnancy
Placenta Perfusion and Sufficiency Study
This study is testing if it's possible to measure blood flow to the placenta in pregnant women between 14 and 16 weeks to help with future research on placenta-related issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Maxima Medical Center Academic / other |
| Locations | 1 site (Veldhoven, Braband) |
| Trial ID | NCT06042348 on ClinicalTrials.gov |
What this trial studies
This observational pilot study aims to assess the feasibility of measuring blood flow to and from the uterus using ultrasonography between 14 and 16 weeks of gestation. The study will recruit women with singleton pregnancies who are attending their routine ultrasound appointment. Participants will undergo a measurement day where they will rest in a supine position while blood flow measurements are taken. The goal is to evaluate the viability of these measurements for future research on placenta-related conditions.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older with singleton pregnancies between 14 and 16 weeks of gestation and a BMI under 30.
Not a fit: Patients with multiple gestations, congenital anomalies, or non-intact pregnancies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of placental health and its impact on pregnancy outcomes.
How similar studies have performed: While this approach is novel in measuring placental perfusion at this early stage, similar studies have shown promise in understanding placental health.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Between 14-16 weeks gestation on measurement day * Placenta anterior * BMI \< 30kg/m2 * Ability to give consent * Adequate mastery of the Dutch or English languages Exclusion Criteria: * Non-intact pregnancy at 13 week's gestational echo. * Vanishing twin * Multiple gestations * Congenital or anatomical anomalies at 13 weeks' gestational echo.
Where this trial is running
Veldhoven, Braband
- Maxima Medical Center — Veldhoven, Braband, Netherlands (Recruiting)
Study contacts
- Principal investigator: Loes Monen — Maxima Medical Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.